Judah Frommer
Stock Analyst at Morgan Stanley
(3.03)
# 1,386
Out of 4,734 analysts
178
Total ratings
58.46%
Success rate
5.21%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Maintains: Underweight | $8 → $6 | $4.58 | +31.00% | 2 | Jan 13, 2025 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $29.94 | +3.56% | 1 | Nov 21, 2024 | |
| RGNX REGENXBIO | Assumes: Overweight | $22 | $7.37 | +198.51% | 1 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $66.48 | +59.45% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $12.11 | +189.02% | 1 | Oct 8, 2024 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $38 | $23.76 | +59.93% | 2 | Apr 22, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $4.00 | +225.00% | 1 | Apr 4, 2024 | |
| PROK ProKidney | Assumes: Equal-Weight | $3 | $1.66 | +80.72% | 1 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Outperform | $40 | $5.51 | +625.95% | 8 | Aug 14, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Outperform | $13 | $1.65 | +687.88% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $28.92 | +3.73% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $9.36 | +145.73% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $43.84 | +14.05% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $118.00 | +19.49% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.50 | +766.67% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.46 | +516.44% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $23.55 | -6.58% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $6.67 | +5.03% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $3.96 | +102.02% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $13.49 | +240.99% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.21 | +216.74% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $14.05 | +291.46% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $72.51 | -36.56% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $87.73 | -44.15% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $943.19 | -60.77% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $68.31 | -54.62% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $73.07 | +4.01% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $68.44 | +165.93% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $72.07 | +48.47% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $106.86 | -11.10% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $19.64 | -8.35% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $90.64 | +27.98% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $95.05 | -60.02% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $139.25 | -84.20% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $58.36 | -40.03% | 9 | Apr 29, 2020 |
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Underweight
Price Target: $8 → $6
Current: $4.58
Upside: +31.00%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $29.94
Upside: +3.56%
REGENXBIO
Nov 15, 2024
Assumes: Overweight
Price Target: $22
Current: $7.37
Upside: +198.51%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $66.48
Upside: +59.45%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $12.11
Upside: +189.02%
Galapagos NV
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $38
Current: $23.76
Upside: +59.93%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $4.00
Upside: +225.00%
ProKidney
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.66
Upside: +80.72%
Jasper Therapeutics
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $5.51
Upside: +625.95%
Acumen Pharmaceuticals
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.65
Upside: +687.88%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $28.92
Upside: +3.73%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $9.36
Upside: +145.73%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $43.84
Upside: +14.05%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $118.00
Upside: +19.49%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.50
Upside: +766.67%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.46
Upside: +516.44%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $23.55
Upside: -6.58%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $6.67
Upside: +5.03%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $3.96
Upside: +102.02%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $13.49
Upside: +240.99%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.21
Upside: +216.74%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $14.05
Upside: +291.46%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $72.51
Upside: -36.56%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $87.73
Upside: -44.15%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $943.19
Upside: -60.77%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $68.31
Upside: -54.62%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $73.07
Upside: +4.01%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $68.44
Upside: +165.93%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $72.07
Upside: +48.47%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $106.86
Upside: -11.10%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $19.64
Upside: -8.35%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $90.64
Upside: +27.98%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $95.05
Upside: -60.02%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $139.25
Upside: -84.20%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $58.36
Upside: -40.03%